Education
About Us
Working with TipRanks
Follow Us
Hikma Pharmaceuticals PLC (DE:H5P)
FRANKFURT:H5P
Earnings Data
Report Date
Aug 06, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
―Last Year’s EPS
1.03Same Quarter Last Year
Moderate Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a balanced but constructive outlook: the company shows solid underlying strength (25% group EBITDA, Rx margin recovery, #1 position in MENA, strong Europe performance, growing RTU pipeline and a GBP 250m buyback) while acknowledging meaningful near-term headwinds concentrated in the injectable division (margin reset, delayed launches, and reduced CMO volume until U.S. capacity ramps around 2028). Management has committed to higher R&D (5-6% of sales), centralized R&D spending and targeted investments to drive medium- to long-term growth, accepting short-term margin pressure. Given the broad-based positives across Rx, branded and MENA, together with a clear action plan for injectables and CMO capacity build-out, the tone is cautiously optimistic.Company Guidance
Strong Group Profitability
Group EBITDA margin at ~25%, materially ahead of many peers (peers targeting ~22%), demonstrating strong overall profitability and operational leverage.
Rx (Generics) Turnaround and Margins
Rx/generics business delivering close to 20% margins with EBIT cited around GBP 200m (management highlighted prior target of GBP 100-130m EBIT and said the division has materially outperformed expectations).
MENA and Branded Growth Momentum
Hikma was #1 company in MENA this year; branded business accelerating to guidance of ~7-8% growth (up from historic ~5-6%), driven by licensing deals and regional expansion.
Europe Injectables Growth & Commercial Execution
Europe injectables grew ~23% this year; management highlighted strong hospital/government demand and differentiated supply reliability as growth drivers.
RTU (Ready-to-Use) Pipeline and Initial Traction
RTU platform with ~15 ready-to-use products in the pipeline; TYZAVAN (vancomycin RTU) launch showing encouraging early momentum — converted ~13% of the gram market for the existing vancomycin bag and existing customers represent ~15% of ~22,000 potential sites.
Increased R&D Commitment and Centralization
R&D budget moved to corporate and increased materially — target now ~5-6% of group sales; management noted an overall R&D spend increase of roughly $45m year-over-year and injectables R&D increase of ~GBP 15m YoY to accelerate pipeline development.
CMO (CDMO) Strategic Investment & Buyback
Company is investing in CMO capability (Bedford site reengineering, hiring Head of CMO) aiming to scale CMO contribution; Rx CMO already ~10% of business this year with target up to ~20% by 2030. Board authorized a GBP 250m share buyback.
DE:H5P Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:H5P Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 26, 2026 | €19.00 | €16.20 | -14.74% |
Aug 07, 2025 | €21.29 | €20.11 | -5.56% |
Feb 26, 2025 | €26.91 | €25.17 | -6.48% |
Aug 08, 2024 | €20.46 | €21.61 | +5.61% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Hikma Pharmaceuticals PLC (DE:H5P) report earnings?
Hikma Pharmaceuticals PLC (DE:H5P) is schdueled to report earning on Aug 06, 2026, TBA (Confirmed).
What is Hikma Pharmaceuticals PLC (DE:H5P) earnings time?
Hikma Pharmaceuticals PLC (DE:H5P) earnings time is at Aug 06, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Hikma Pharmaceuticals PLC stock?
The P/E ratio of Hikma Pharmaceuticals is N/A.
What is DE:H5P EPS forecast?
Currently, no data Available